Metastatic melanoma: The new era of targeted therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Guida, Michele ^a   Pisconte, Salvatore ^b   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

metastatic melanoma; new drugs; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DABRAFENIB; GDC 0973; GLYCOPROTEIN GP 100; INTERLEUKIN 2; IPILIMUMAB; LENVATINIB; MELANOMA ANTIGEN 3; PLACEBO; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; URELUMAB; VEMURAFENIB;

ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TARGETING; FATIGUE; FEVER; HUMAN; IMMUNOREGULATION; IMMUNOTOXICITY; KERATOACANTHOMA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY DISORDER; RASH; SIDE EFFECT; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84858988078     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.645807     Document Type: Article

References (69)

1. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:5426-34 (Pubitemid 350232219)
2. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011;47:2150-7
3. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988;18:1901-5 (Pubitemid 19046203)
4. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16 (Pubitemid 29318842)
5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004;101(suppl 2):14639-45 (Pubitemid 39346736)
6. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-23
7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 Blockade. Science 1996;271:1734-6 This is a key paper regarding the antitumoral activity of anti CTLA4 monoclonal antibody.
8. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 (Pubitemid 46160986)
9. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9 (Pubitemid 46630658)
10. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77 (Pubitemid 46217464)
11. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81
12. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. ASCO meeting 2008. J Clin Oncol 2008;26(20 Suppl):abstract LBA9011
13. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010;16:1042-8
14. Pennock GK, Waterfield W, Wolchok JD. Patient responses to Ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 2011; [Epub ahead of print]
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase II, dose-ranging study. Lancet Oncol 2010;11:155-64
16. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23 This is the registrative study of the monoclonal antibody anti CTLA4 Ipilimumab for second-line metastatic melanoma therapy.
18. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9
19. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26 This is the registrative study of the monoclonal antibody anti CTLA4 Ipilimumab as first line-therapy in metastatic melanoma.
20. Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract 8583
21. Heller KN, Pavlick AC, Hodi FS, et al. Safety and survival analysis of ipilimumab therapy in patients withstable asymptomatic brain metastases. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract 8581
22. Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. ASCO meeting 2010. J Clin Oncol 2010;28(15(Suppl):abstract 8523
23. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-63 (Pubitemid 44288958)
24. Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract 8511
25. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 2007;27:111-22 (Pubitemid 47089023)
26. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-51
27. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 (Pubitemid 46160986)
28. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). ASCO Meeting 2008. J Clin Oncol 2008;26(Suppl):abstract 3007
29. Bot A, Obrocea M, Marincola F. Cancer vaccines: from research to clinical practice. Informa Healthcare; London: 2011
30. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are co-ordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62 (Pubitemid 41698748)
31. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002;236:785-93 (Pubitemid 35403234)
32. Koyanagi O'Day SJ, HoonDS, Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010(16):2402-8
33. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014-21
34. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-17
35. Kruit WH, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). ASCO meeting 2008. J Clin Oncol 2008;26(20 Suppl):abstract 9065
36. Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009;9:5
37. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
38. Riker AI, Vahanian NN, Link CJ, et al. Combination immunotherapy for high-risk and advanced melanoma patients. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract 8534
39. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009;15:6267-76
40. Yuan J, Ginsberg B, Page D, et al. CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011;60:1137-46
41. Hu JC, Coffin RS, Davis CJ, et al. A Phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47 (Pubitemid 44876843)
42. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. ASCO Meeting 2008. J Clin Oncol 2008;26:abstract 9008
43. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91 (Pubitemid 32751626)
44. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010;20:218-26
45. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-20 (Pubitemid 46733089)
46. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8
47. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54 (Pubitemid 34716871)
48. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62 (Pubitemid 43128863)
49. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47 This is the key paper regarding the new biomolecular classification of melanoma patients. (Pubitemid 41653105)
50. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6 (Pubitemid 46630793)
51. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46
52. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broadtarget blockade in BRAF-mutant melanoma. Nature 2010;467:596-9 This is one of the first studies showing the clinical activity of BRAF inhibitors in BRAF-mutated melanoma.
53. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19 This is one of the first papers demonstrating the activity of an anti BRAF drug in BRAF-mutated melanoma.
54. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. ASCO meeting 2011. J Clin Oncol 2010;28(15 Suppl):abstract 8503
55. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16 This is the registrative study of the anti BRAF drug vemurafenib as first-line therapy in metastatic melanoma patients.
56. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation positive melanoma. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl): abstract 8509
57. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (METS) [abstract LBA27]. 35th Congress of the European Society for Medical Oncology (ESMO); 8-12 October 2010
58. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102:1724-30
59. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
60. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract CRA8503
61. Terheyden P, Houben R, Pajouh P, et al. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol 2010;130:314-16
62. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010;80:568-74
63. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11 (Pubitemid 43673217)
64. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. ASCO meeting 2009. J Clin Oncol 2009;27(15 Suppl):abstract 9001
65. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
66. Larkin JM, Turajlic S, Nathan PD, et al. A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract TPS229
67. Glen H, Mason S, Patel H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309
68. Funahashi Y, Matsui J, Minoshima Y, et al. The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma. ASCO 2011. J Clin Oncol 2011;29(Suppl):abstract 8566
69. Hong DS, Boss DS, Glen H, et al. Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials. ASCO meeting 2011. J Clin Oncol 2011;29(Suppl):abstract 8527